Five CVOTs, namely, LEADER3, SUSTAIN-6, REWIND, HARMONY, and AMPLITUDE-O [73] have consistently shown the safety and efficacy of GLP-1 agonists in patients with T2DM and have provided evidence of a secondary preventive effect of GLP-1 agonists in T2DM patients with CVD and kidney disease. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.